No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
GC Corp. is engaged in the manufacture of pharmaceutical products and oversees the establishment and coordination of business strategies for Green Cross subsidiaries, including business launch and investment portfolio management. The company's prescription drug portfolio includes blood derivatives, cerebrovascular disease treatments, fibrinolytic agents, vaccines, hunter syndrome therapies, herbal medicines, and recombinant products. It also offers over-the-counter drugs such as skin disease treatments and topical non-steroidal anti-inflammatories. GC Corp. was founded on October 5, 1967, and is headquartered in Yongin-si, South Korea.
www.gccorp.comNo one on the platform currently holds 005257.KS.
No tracked institution reports a position in 005257.KS as of their last filing.
No one on the platform has traded 005257.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 18.5% | 5.8% | ||||
| Profit Margin % | -0.2% | 1.7% | 2.5% | |||
| Free Cash Flow Margin % | 1.4% | -2.2% | -3.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $113.8B | +0.0% | $687.00 | $687.00–$687.00 | — | 1 |
| 2027 | $113.4B | -0.4% | $670.00 | $670.00–$670.00 | — | 1 |
| 2028 | $115.8B | +2.1% | $690.00 | $690.00–$690.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 005257.KSGC Corp. | $17890.00 | +2.23% | $537.7B | — |
| 005690.KSPharmicell Co., Ltd. | $10860.00 | -0.91% | $651.6B | — |
| 053030.KQBINEX Co., Ltd. | $6380.00 | -1.09% | $203.2B | — |
| 078160.KQMEDIPOST Co., Ltd. | $8700.00 | +0.00% | $340.0B | — |
| 085660.KQChabiotech Co.,Ltd. | $7950.00 | +0.13% | $735.4B | — |
| 086900.KQMedy-Tox Inc. | $68700.00 | -0.15% | $447.8B | — |
| 228760.KQGenomictree Inc. | $10130.00 | +0.50% | $248.5B | — |
Source: Financial Modeling Prep · peers by sector/industry